🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Missed the FDA ODAC meeting today? Catch up on a meta-analysis of the DREAMM-7 and DREAMM-8 trials, which found that belantamab mafodotin is linked to high ocular toxicity in patients with relapsed or refractory #myeloma. ➡️ buff.ly/JEXWPaF

🎉 Out now! 🎉 In an Editor’s Special episode of The HemOnc Pulse, Tycel Phillips, MD (Tycel Phillips), of City of Hope, discusses the evolving treatment landscape for B-cell non-Hodgkin #lymphoma. 🎧 Listen here: buff.ly/vcU62l1

TGIF! Here's your weekly HemOnc rundown: ⭐ The FDA ODAC voted against belantamab mafodotin combinations for #myeloma in its proposed dosing ⭐ Danilov Lab joined our podcast to discuss unmet needs in #CLL ⭐ Our July print issue is now live 📚 ➡️ buff.ly/bYNjS6S

The Pan Pacific Leukemia Conference just wrapped up in Lahaina, Hawaii 🌴 Sign up for our newsletter and stay tuned for exclusive interviews and coverage coming soon! #2025PPLC ➡️ buff.ly/wHpf56a

🙌 ICYMI: Amer Zeidan MBBS,MHS ‏عامر زيدان, of Yale Cancer Center, discussed the phase 1/2 BEXMAB study of bexmarilimab plus azacitidine and what the results mean for #MDS care. 📺 Watch here: buff.ly/BdUuylH

Pierre Fabre Pharmaceuticals announced development updates for tabelecleucel for EBV+ PTLD, including a transfer of the Investigational New Drug Application and resubmission of the Biologics License Application. ➡️ buff.ly/duqnFKU

Belantamab mafodotin was in the hot seat on Thursday as the FDA'S ODAC voted that the BCMA-targeting drug is unfavorable in its proposed dosing, with concerns of high ocular toxicity. 📚 Read more: buff.ly/9MmXaoO

The FDA recently approved linvoseltamab for the treatment of relapsed or refractory multiple #myeloma. Hear Joshua Richter, MD, FACP, of The Tisch Cancer Institute, talk about results of the LINKER-MM1 study that led to FDA approval. ➡️ buff.ly/2gLMfrb

Before heading back to the office on Monday, check out the latest episodes of The HemOnc Pulse! Our last three Editor's Special episodes feature Drs. Amir Fathi, Danilov Lab, and Tycel Phillips in conversation with BCT's Managing Editor. 🎧 buff.ly/Qh0nHjz

ICYMI: Nicole Lamanna, MD, of Columbia Medicine, discusses results from a network meta-analysis evaluating BTK inhibitors in patients with relapsed/refractory #CLL with high-risk cytogenetic features. ➡️ buff.ly/rhkHl63

Revumenib is currently under FDA priority review for relapsed or refractory NPM1-mutated #AML. Read about the "promising" efficacy of revumenib in patients with NPM1-mutated #AML in a study led by Ghayas Issa of MD Anderson Cancer Center. ➡️ buff.ly/iMsVBao

🙌 Doris Hansen, MD, of Moffitt Cancer Center, discussed the evolving treatment landscape for multiple #myeloma, innovations in T-cell–based therapies, and the implications of recent clinical trial data. 📺 Watch the interview here! buff.ly/2pizWdZ

ICYMI: In a retrospective review presented at #ASCO25, patients with newly diagnosed #myeloma were considered to be at high risk for venous thromboembolism if they had a SAVED score of 2 or higher or an IMPEDE score of 4 or higher. 📰 buff.ly/0Y95VIR

❌ Luspatercept-aamt plus JAK inhibitor therapy did not meet its primary end point of producing red blood cell transfusion independence for patients with #myelofibrosis-associated anemia in the INDEPENDENCE trial. 📰 Read more: buff.ly/wDIj7Tt

Five-year CARTITUDE-1 data presented at #ASCO25 by Peter Voorhees, MD, highlights cilta-cel’s lasting impact in relapsed or refractory multiple #myeloma. 📰 Read more: buff.ly/a8ClIiM

Daratumumab outperforms active monitoring in patients with high-risk smoldering multiple #myeloma, according to a study led by Thanos Dimopoulos, of University of Athens, and published in NEJM. 📰 buff.ly/FwLBpoX

Out now! 🎉 In this opening segment from an expert panel discussion, Drs. Saeed Sadeghi (UCLA Health), Clark Alsfeld (Ochsner Health), Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO (Duke Health), and Raji Shameem (Orlando Health) discuss first-line management for low-risk #MDS. ➡️ buff.ly/41JBrfS

All patients with anti-BCMA/-GPRC5D naïve multiple #myeloma who received the recommended phase 2 dose of JNJ-5322 in a phase 1 study achieved an objective response. Read more, with insight from study investigator Rakesh Popat of UCLH. ➡️ buff.ly/jbjYqiZ

In the next #MDS roundtable episode, Drs. Saeed Sadeghi (UCLA Health), Clark Alsfeld (Ochsner Health), Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO (Duke Health), and Raji Shameem (Orlando Health) discuss the COMMANDS trial of luspatercept versus epoetin alfa. ➡️ buff.ly/V0VkH5Z

Happy Friday! What's new on BCT this week? ✔️ Dr. Tycel Phillips joined our podcast to discuss the treatment landscape for B-cell non-Hodgkin #lymphoma ✔️ An expert #MDS roundtable explored how low-risk disease is managed ✔️ New data from CARTITUDE-1 ➡️ buff.ly/bYNjS6S